Profiel
Fabrice Piu worked as a Director of Chemical Genomics at ACADIA Pharmaceuticals, Inc. and as a Vice President of Research & Preclinical Development at Otonomy, Inc. He holds a doctorate degree from École Normale Supérieure and undergraduate and graduate degrees from the University of Lyon.
Eerdere bekende functies van Fabrice Piu
| Bedrijven | Functie | Einde |
|---|---|---|
| OTONOMY | Hoofd Techniek/Wetenschap/O&O | 01-01-2023 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Opleiding van Fabrice Piu
| École Normale Supérieure | Doctorate Degree |
| University of Lyon | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
